Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001545672 XXXXXXXX LIVE 4 Common Stock, $0.0001 par value per share 11/17/2025 false 0001832038 00534A102 Invivyd, Inc. 209 Church Street New Haven CT 06510 Philip Chase (603) 643-7110 Adimab, LLC 7 Lucent Drive Lebanon NH 03766 0001545672 N Adimab, LLC OO N DE 20454490 20454490 20454490 N 8.8 OO Limited Liability Company Common Stock, $0.0001 par value per share Invivyd, Inc. 209 Church Street New Haven CT 06510 This Amendment No. 4 ("Amendment No. 4") amends and supplements the Schedule 13D originally filed by Adimab, LLC (the "Reporting Person") with the Securities and Exchange Commission (the "Commission") on March 30, 2022, as amended and supplemented by Amendment No. 1 thereto, filed with the Commission on April 26, 2022, Amendment No. 2 thereto, filed with the Commission on June 24, 2022 and Amendment No. 3 thereto, filed with the Commission on January 22, 2024 (the "Original 13D," and together with this amendment, the "Schedule 13D"). Only those items that are hereby reported are amended; all other items reported in the Original 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 4 have the meanings ascribed to them in the Original 13D. This Amendment is being filed to report that the beneficial ownership of Common Stock by the Reporting Person has decreased by more than 1% as a result of the sales reported in Item 5. Item 2 of the Schedule 13D is hereby amended and restated as follows: (a) The Schedule 13D is being filed by Adimab, LLC (the "Reporting Person"), a Delaware limited liability company. Information with respect to the directors and executive officers of the Reporting Person (collectively, the "Related Persons") is included in Appendix A to this Schedule 13D. (b) The business address of the Reporting Person is 7 Lucent Drive, Lebanon, NH 03766. (c) The Reporting Person's principal business is to provide therapeutic antibody discovery and enginerring technologies. (d) None (e) None (f) The Reporting person is a Delaware limited liability company. Item 5 of the Schedule 13D is hereby amended and restated as follows: (a) Amount beneficially owned: 21,687,906; Percent of Class: 8.8%. The above percentage is based on 233,122,834 shares of Common Stock outstanding as of October 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. (b) The Reporting Person has sole voting and sole dispositive power with respect to all of the shares of Common Stock that it beneficially owns. On November 17, 2025, the Reporting Person sold 1,233,416 shares of Common Stock at a weighted average price of $3.0026 per share in a series of open market transactions. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.045 per share. The Reporting Person undertakes to provide to the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. None Not applicable Adimab, LLC /s/ Philip Chase Philip Chase, Chief Executive Officer 11/19/2025